数据驱动的加权发作评分可准确预测系统性红斑狼疮器官损伤
基于354例活动性SLE患者的多中心纵向队列(中位随访66个月),采用随机森林和混合效应模型构建加权发作评分,并在110例独立队列中验证。评分≥3.5识别的高风险发作(占40%)与后续损伤关联最强(IRR 2.49,95%CI 1.51-4.10),验证队列AUC 0.893优于原SFI的0.816。
要点
- 轻中度和重度SFI发作均升高12个月损伤风险(IRR分别为1.42和1.54)。
- 需高剂量糖皮质激素的主要器官受累权重最高(6分),孤立激素升级权重1.5-3。
- 评分≥3.5的高风险发作占40%,与损伤关联最强且预测优于原SFI。
核心结论
- 新型加权SLE发作评分能更好预测器官损伤累积,可能支持达标治疗实施和临床试验设计。
研究设计与样本
- 多中心纵向队列纳入354例入组时需治疗的活动性SLE患者,中位随访66个月,发作采用改良SFI判定。
- 使用随机森林和改良发作定义评估SFI各变量对后续损伤的贡献,通过bootstrap验证的混合效应模型推导发作评分。
- 在独立队列(n=110)中验证评分性能。
主要发现
- 轻中度和重度SFI发作均与12个月损伤风险升高相关(IRR分别为1.42和1.54)。
- SFI子标准中,需高剂量糖皮质激素的主要器官受累对损伤预测权重最高(6分),孤立激素升级权重1.5-3,次要器官受累和加用免疫抑制剂/生物制剂权重较低(各1分)。
- 基于这些子标准的发作评分预测性能良好(Brier评分0.07)。
- 阈值≥3.5识别的高风险发作(占全部发作40%)与后续损伤关联最强(IRR 2.49,95%CI 1.51-4.10)。
- 验证队列中评分优于原SFI定义(AUC-ROC 0.893 vs 0.816)。
关键数值与推荐
- 发作评分阈值≥3.5定义为高风险发作,占全部发作40%。
- 高风险发作与后续损伤的IRR为2.49(95%CI 1.51-4.10)。
- 验证队列AUC-ROC为0.893(新评分)vs 0.816(原SFI)。
- Brier评分为0.07。
临床怎么用
- 可将加权发作评分用于SLE患者发作风险评估,评分≥3.5提示高风险发作,需加强损伤监测。
- 持续DORIS(>50%时间)可能有助于降低高风险发作,支持达标治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Flares are key determinants of outcome in systemic lupus erythematosus (SLE), yet the conventional mild/moderate vs severe classification inadequately reflects prognosis. We sought to refine flare classification to improve damage prediction and develop a data-driven flare score. METHODS: We analysed a multicentre longitudinal cohort of 354 patients with active SLE requiring treatment at inclusion (median follow-up 66 months). Flares were adjudicated using a modified Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index Flare Index (SFI). Random Forests and modified flare definitions assessed the contribution of individual SFI variables to subsequent damage. We derived a flare score using bootstrap-validated mixed-effects models. This was validated in an independent cohort (n = 110). RESULTS: Both mild/moderate and severe SFI flares contributed to elevated 12-month damage risk (incidence rate ratio [IRR]:1.42 and 1.54, respectively). Among SFI subcriteria, major organ involvement requiring high-dose glucocorticoids (GCs) ranked highest for damage prediction (weight = 6), followed by the isolated GCs escalation criteria (weights = 1.5-3), whereas minor organ involvement and immunosuppressants/biologics addition carried lower weights (1 each). A flare score based on these subcriteria demonstrated good predictive performance (Brier score = 0.07). A threshold of ≥ 3.5 identified a subset of high-risk flares (40% of all episodes) that displayed the strongest association with subsequent damage (IRR: 2.49, 95% CI: 1.51-4.10) and outperformed the original SFI definition in the validation cohort (area under the curve-receiver operating characteristic: 0.893 vs 0.816). Although both Definitions of Remission in SLE (DORIS) and lupus low disease activity state correlated with lower risk of SFI-defined flares, only sustained DORIS (>50% of time) reduced high-risk flares. CONCLUSIONS: We defined and validated a novel weighted SLE flare score that better predicts damage accrual and may support treat-to-target implementation and clinical trial design.
引用
- Nikolopoulos D, Pitsigavdaki S, Nöthling DM, et al. A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus. Ann Rheum Dis. 2026. PMID: 42399124. doi:10.1016/j.ard.2026.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。